肿瘤患者中肝炎病毒感染状况分析

目的　了解肝炎病毒在肿瘤患者这一特殊群体中的感染现状 ,探讨肝炎病毒感染与肿瘤发生之间的相关性。方法　应用ELISA方法对 16 2 0份肿瘤患者的临床血样的乙型肝炎表面抗原 (HBsAg)、丙型肝炎病毒抗体 (抗 HCV)、戊型肝炎病毒抗体 (抗 HEV)和庚型肝炎病毒抗体 (抗 HGV)进行了检测。结果　肿瘤患者中HBsAg ,抗 HCV ,抗 HEV ,抗 HGV的感染率分别为 6 7% ,2 7 6 % ,10 8% ,2 5 % ,且总感染率为 5 7 7% ;肝癌患者中HBsAg ,抗 HCV ,抗 HEV ,抗 HGV的感染率分别为 39 3 % ,2 7 9% ,9 8% ,6 6 % ,且总感染率为 83 6 % ;非肿瘤患者中HBsAg ,抗 HCV ,抗 HEV ,抗 HGV的感染率分别为 8 7% ,3 6 % ,1 9% ,0 8% ,且总感染率为 15 1%。经 χ2 检验 ,肿瘤患者与非肿瘤患者之间 ,肝癌患者与非肿瘤患者之间感染率有明显差异 (P <0 .0 5 )。同时发现 3组患者中均有重叠感染现象。结论　肝炎病毒的感染与某些组织或器官肿瘤的发生存在着一定的相关性。

Study on the Hepatitis Virus Infection among the Patients of Cancer

Objective In order to find out the present situation of hepatitis virus infection among the patients of cancer and the relativity between the infection of hepatitis virus and the occurrence of cancer. Method 1 620 patients of cancer were studied on their serum HBsAg, anti HCV, anti HEV and anti HGV with ELISA. Result The infection rates of HBsAg, HCV, HEV and HGV. of the patients of cancer (not including liver cancer) were 16.7%, 27.6%, 10.8% and 2.5% respectively with an overall infection rate of 57.7%. The infection rates of HBsAg, HCV, HEV and HGV. of the patients of liver cancer were 39.3%, 27.9%, 9.8% and 6.6% respectively with an overall infection rate of 83.6%. The infection rates of HBsAg, HCV, HEV and HGV. of the patients (not including cancer) were 8.7%, 3.6%, 1.9% and 0.8% respectively with an overall infection rate of 15.1%. The infection rates for the patients of cancer, the patients of liver cancer and the patients were significant difference( P <0.05). We also find out superimposing infection in the patients. Conclusion The result shows that the infection of hepatitis virus probably leads to the occurrence of cancer in other tissues or organs.